REDDS

Red blood cell transfusion thresholds and QoL in myelodysplastic syndromes. A pilot, feasibility study.

Chief investigators: Dr Simon Stanworth and Professor David Bowen
Primary sponsor: NHSBT
Funder: NHSBT Trust Fund Grant

Summary

Red blood cell transfusion thresholds and Quality of Life in myelodysplastic syndromes (MDS). A pilot, feasibility study.

The ultimate goal of this feasibility trial is to inform the design for a large randomised controlled trial to compare a restrictive (transfuse to maintain haemoglobin concentration between 85 and 100g/L) with a liberal (transfuse to maintain haemoglobin concentration between 110-125g/L) red cell transfusion strategy for clinical outcomes.

Study hypothesis

A randomised controlled feasibility trial to evaluate protocol adherence between a restrictive (transfuse to maintain haemoglobin concentration between 85 and 100g/L) and a liberal (transfuse to maintain haemoglobin concentration between 110-125g/L) red cell transfusion strategy.

Study contact

Heather Smethurst
Email: heather.smethurst@nhsbt.nhs.uk
Tel: 07471 177896

Publications

Simon J. Stanworth, Sally Killick, Zoe K. McQuilten, Marina Karakantza, Robert Weinkove, Heather Smethurst, Laura A. Pankhurst, Renate L. Hodge, Valerie Hopkins, Helen L. Thomas, Alison J. Deary, Jeannie Callum, Yulia Lin, Erica M. Wood, Rena Buckstein, David Bowen and on behalf of the REDDS Investigators. Red cell transfusion support in outpatients with myelodysplastic syndromes: a feasibility and exploratory randomised trial. Doi: 10.1111/bjh.16347